China Transcranial Magnetic Stimulation Therapy Brain Treatment System

Name: China Transcranial Magnetic Stimulation Therapy Brain Treatment System
Brand: Zhengzhou Hepo International Trading Co., Ltd.
SKU: 707731342

Henan, ChinaZhengzhou Hepo International Trading Co., Ltd.

US$11,250.00-14,560.00

1 Piece

Sample price:US$14560.00/piece.Request sample

Product profile

Customization

Available

Type

Brain

Function

Activate Brain Endorphin System

Model NO.

HP-CCD910

Theory

Electrotherapeutics

Certification

CE, ISO13485

LCD Display

With LCD Display

Group

Adult

Treatment Range

Cerebrovascular System,Cranial Nervous System

Brain Damage System

Right for Usage

Power

50W

Electrical Source

220V/50Hz

Blood Circulation

Improve The Blood Circulation of The Brain

Repairing Fine Bags

It Can Improve Local Microcirculation

Promote Metabolism

Enhance The Metabolism of Brain Nerve Cells

Self-Repairing

Enhance The Ability of Damaged Cells

Relieve Sclerosis

Enhance The Elasticity of Cerebral Blood Vessels

Prevent Recurrence

Improve The Symptoms of Patients

Relieve Pain

Yes

Transport Package

Carton or Wood Package

Specification

380*380*1150mm

Trademark

HEPOBIO

Origin

China

HS Code

901890

Production Capacity

800 Sets/Month

Company profile

Zhengzhou Hepo International Trading Co., Ltd.

Henan, China

Business Type: Manufacturer/Factory, Trading Company, Group CorporationAverage Response Time: ≤2.29h

AI-Powered supplier vetting

SummaryThe supplier presents established manufacturing and quality-system credentials, with eight production lines, stated output across five medical-equipment categories, broad export coverage, and ISO 13485, ISO 9001, ISO 14001, and GMP certifications. It offers extensive product customization and maintains inventory capability, with stated lead times within 15 working days in both peak and off-season periods. However, evidence also shows material gaps: no written corrective-action or complaint-handling procedures, no documented service-assessment procedure, no environmental impact assessment report, no overseas warehouse or showroom, no recent new-product activity, no ODM or major-brand OEM service, no SDK, zero stated R&D patents, and no available R&D design-control documentation. Financial records are indicated for multiple years, but the slices do not provide sufficient non-financial evidence to assess financial credibility.

Supplier typeThe supplier manufactures medical and biosafety-related equipment, including cold-chain, clinical, first-aid, and laboratory products. It operates eight production lines, describes imported production equipment, and exports to multiple global regions, indicating a manufacturer with broad product and market coverage.

CertificationsThe supplier states that its factories adopted ISO 9001:2008 and ISO 13485 systems, while its supplier-management certifications include ISO 13485, ISO 9001, ISO 14001, and GMP. These explicitly stated certifications support a positive assessment of formal quality and management-system coverage.

R&D capabilityThe supplier has 11–20 years of total R&D-engineer experience and can customize products, but reports no new products during the past year, no SDK, no software-instrument R&D, zero R&D patents, and no available design-input, output, review, verification, or validation documentation. The explicit evidence indicates limited demonstrated innovation infrastructure.

Production capacityThe supplier operates eight production lines and reports production quantities for deep freezers, analyzers, and incubators, alongside inventory capability and broad export markets. Its company description also cites dedicated product solutions and imported production equipment, providing explicit evidence of substantial manufacturing capability.

Customization capabilityThe supplier explicitly offers customization from samples and designs, full, minor, and flexible customization, and assigns R&D engineers to customize products according to customer needs. However, the absence of documented R&D design-control records means process formalization is not demonstrated, while the customization offering itself is clearly supported.